Products of therapeutic insulins in the blood of insulin-dependent (type I) diabetic patients
- PMID: 3886464
- DOI: 10.2337/diab.34.5.510
Products of therapeutic insulins in the blood of insulin-dependent (type I) diabetic patients
Abstract
The tendency of insulin in high concentrations to self-associate and the widespread presence of insulin-degrading enzymes suggest that fragments and/or aggregates of insulin may circulate in normal and insulin-dependent diabetic (IDDM) individuals. To examine this possibility, we have analyzed, by sensitive physicochemical methods, immunoreactive insulin (IRI) taken from the blood of 9 healthy volunteers and 12 insulin-dependent diabetic patients. IRI from the blood of the normal volunteers was composed of 6000 (91.0 +/- 1.4%) and 9000 (9.0 +/- 1.4%) molecular weight (mol wt) material. By 10% polyacrylamide disc gel electrophoresis (PAGE) and reverse-phase, high-performance liquid chromatography (HPLC), the 6000 mol wt material was indistinguishable from human insulin standards and insulin fragments were not found. C-peptide reactivity in the 9000 mol wt material confirmed the expected presence of proinsulin and intermediates of proinsulin conversion. IRI harvested from the blood of 12 C-peptide-negative IDDMs, using a variety of insulin preparations, also separated into 6000 (80.5 +/- 3.9%) and 9000-12,000 (19.5 +/- 3.9%) mol wt material. By HPLC, 6000 mol wt IRI was either pork insulin (in volunteers using pure pork insulin) or a mixture of beef (approximately 90%), pork (approximately 10%) and deamidated beef (trace) insulin in those using a beef-pork mixture. However, the 9000-12,000 mol wt material had characteristics entirely distinct from proinsulin of either human or animal origin: C-peptide reactivity was undetectable using any of three sensitive radioimmunoassay systems, on PAGE it migrated more rapidly than proinsulin-like material, and in contrast to proinsulin, it was unaffected by proteolytic degradation.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Biochemical and clinical implications of proinsulin conversion intermediates.J Clin Invest. 1985 Oct;76(4):1398-405. doi: 10.1172/JCI112116. J Clin Invest. 1985. PMID: 3902891 Free PMC article.
-
Familial hyperproinsulinemia. Two cohorts secreting indistinguishable type II intermediates of proinsulin conversion.J Clin Invest. 1984 Mar;73(3):714-9. doi: 10.1172/JCI111264. J Clin Invest. 1984. PMID: 6368587 Free PMC article.
-
A new case of familial hyperproinsulinemia.Endocrinol Jpn. 1989 Aug;36(4):545-52. doi: 10.1507/endocrj1954.36.545. Endocrinol Jpn. 1989. PMID: 2684621
-
Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM.Diabetes. 1997 Nov;46(11):1725-32. doi: 10.2337/diab.46.11.1725. Diabetes. 1997. PMID: 9356018
-
Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience.Diabetes Care. 1992 May;15(5):666-92. doi: 10.2337/diacare.15.5.666. Diabetes Care. 1992. PMID: 1516487 Review.
Cited by
-
The source of the circulating aggregate of insulin in type I diabetic patients is therapeutic insulin.J Clin Invest. 1986 Mar;77(3):717-23. doi: 10.1172/JCI112366. J Clin Invest. 1986. PMID: 3512601 Free PMC article.
-
Hepatic glucagon metabolism. Correlation of hormone processing by isolated canine hepatocytes with glucagon metabolism in man and in the dog.J Clin Invest. 1987 Feb;79(2):409-17. doi: 10.1172/JCI112827. J Clin Invest. 1987. PMID: 2879853 Free PMC article.
-
Insulin-dependent (type I) diabetes mellitus.CMAJ. 1991 Nov 15;145(10):1227-37. CMAJ. 1991. PMID: 1933705 Free PMC article. Review.
-
The cell biology of systemic insulin function.J Cell Biol. 2018 Jul 2;217(7):2273-2289. doi: 10.1083/jcb.201802095. Epub 2018 Apr 5. J Cell Biol. 2018. PMID: 29622564 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical